QXQingxin Xia

Qingxin Xia

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Qingxin Xia has a total of 35 co-authors. Here are the top co-authors by number of shared publications:

  • He Zhang

    Department of Pathology, Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, Henan, China

    3 shared publications
  • Beibei Ren

    Department of Pathology, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China

    2 shared publications
  • Bing Zhang

    Department of Pathology, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China

    2 shared publications
  • Yi Wang

    Department of Pathology, Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, Henan, China

    2 shared publications
  • Chaolong Peng

    Department of Pathology, The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, China

    1 shared publication
  • Dadong Zhang

    Department of Clinical and Translational Medicine, 3D Medicines Inc., Shanghai, China

    1 shared publication

Latest Publications

  • Open Access

    The application of tumor origin genetic testing in differential diagnosis of breast metaplastic carcinoma

    by Beibei Ren, Bing Zhang, Xiangnan Jiang, He Zhang, Qingxin Xia

    Metaplastic breast carcinoma comprises a heterogeneous group of morphologic variants characterized by markedly aggressive pathological behavior and diverse histological subtypes. Accurate diagnosis of metaplastic breast carcinoma is essential for implementing effective and individualized treatment approaches; however, its differentiation from similar tumors may occasionally be challenging. We report two cases of breast tumors diagnosed using comprehensive tumor genome analysis.

  • Open Access

    TP53 mutation and immunohistochemical p53 expression characteristics in diffuse large B–cell lymphoma

    by Yiping Jin, Yi Wang, Lu Wang, He Zhang, Beibei Ren, Jiawen Zheng, Qingxin Xia, Yanyan Liu

    Diffuse large B-cell lymphoma (DLBCL) with TP53 mutations has specific clinicopathological features and is usually associated with a poor prognosis. TP53 gene mutations typically lead to aberrant expression patterns of the p53 protein. We studied 123 DLBCL patients at Henan Cancer Hospital, 35.8% (44/123) had TP53 mutations. Analysis of mutation sites in 44 cases of DLBCL patients revealed that the mutations primarily occur in the DNA-binding domain (DBD region) of the encoded p53 protein; among all mutation types, there were 8 truncation or frameshift mutations, and 36 missense mutations. Further, immunohistochemistry (IHC) detected expression levels of p53 protein in 123 DLBCL samples. The mutation results were used as a reference, and receiver operating characteristic (ROC) curve analysis was employed. Ultimately, the expression ratio of 65% and the moderate–strong expression intensity were regarded as the cut–off value, namely high p53 expression or p53 negative (<1%) indicated mutant–type p53 protein. the complete remission (CR) rate of the mutant–type p53 protein group after receiving R–CHOP regimen was 50% (14/28), and the objective response rate (ORR) was 75%, which differed significantly (P<0.01) compared with wild–type p53 protein group [CR rate of 75.86% (66/87) and ORR rate of 89.66%]. Common gene mutations in the mutant–type p53 protein group primarily involve alterations in pathways related to epigenetics, B cell antigen receptor signaling, cell cycle, among others. IHC analysis of the p53 protein is a simple and low-cost approach that can be employed to predict TP53 mutation status and therapy response.


  • Open Access

    Dramatic Response to Ensartinib in Metastatic Neuroendocrine Tumors With a Novel CEP44‐ALK Fusion: A Case Report and Literature Review

    by Haiyang Chen, Yingxi Wu, Xuan Wu, Kai Wang, Qingxin Xia, Qiming Wang

    Neuroendocrine tumor (NET) is a deadly malignancy disease that can be found anywhere in the body. The lack of tumor‐specific treatment led to the worse prognosis of NET. Anaplastic lymphoma kinase‐tyrosine kinase inhibitors (ALK‐TKIs), such as alectinib and crizotinib, have been used in the treatment of NET patients with ALK rearrangement. However, the response to ensatinib in NET patients with rare ALK fusion has been rarely reported. Here, we report a 55‐year‐old Chinese female patient with NET (atypical carcinoid tumor) and a novel CEP44‐ALK rearrangement identified by next‐generation sequencing (NGS). NGS can provide more information on mutation landscape for rare neuroendocrine tumors to guide treatment and assist in clinical decisions by presenting molecular changes. The patient received ensartinib (225 mg/day) for 18 months until disease progression in June 2024 and achieved a radiographic partial response. Although patients with ALK fusions showed response to ensatinib in nonsmall cell lung cancer (NSCLC), this study first reports a metastatic NET case with a novel CEP44‐ALK rearrangement that responded favorably to ensartinib.


  • CD24 blockade as a novel strategy for cancer treatment

    by Yawen Wang, Haoran Yu, Mengyuan Yu, Hui Liu, Bing Zhang, Yuanyuan Wang, Simin Zhao, Qingxin Xia


  • Open Access

    Artificial Intelligence-Assisted Score Analysis for Predicting the Expression of the Immunotherapy Biomarker PD-L1 in Lung Cancer

    by Guoping Cheng, Fuchuang Zhang, Yishi Xing, Xingyi Hu, He Zhang, Shiting Chen, Mengdao Li, Chaolong Peng, Guangtai Ding, Dadong Zhang, et al.

    Programmed cell death ligand 1 (PD-L1) is a critical biomarker for predicting the response to immunotherapy. However, traditional quantitative evaluation of PD-L1 expression using immunohistochemistry staining remains challenging for pathologists. Here we developed a deep learning (DL)-based artificial intelligence (AI) model to automatically analyze the immunohistochemical expression of PD-L1 in lung cancer patients. A total of 1,288 patients with lung cancer were included in the study. The diagnostic ability of three different AI models (M1, M2, and M3) was assessed in both PD-L1 (22C3) and PD-L1 (SP263) assays. M2 and M3 showed improved performance in the evaluation of PD-L1 expression in the PD-L1 (22C3) assay, especially at 1% cutoff. Highly accurate performance in the PD-L1 (SP263) was also achieved, with accuracy and specificity of 96.4 and 96.8% in both M2 and M3, respectively. Moreover, the diagnostic results of these three AI-assisted models were highly consistent with those from the pathologist. Similar performances of M1, M2, and M3 in the 22C3 dataset were also obtained in lung adenocarcinoma and lung squamous cell carcinoma in both sampling methods. In conclusion, these results suggest that AI-assisted diagnostic models in PD-L1 expression are a promising tool for improving the efficiency of clinical pathologists.


  • Intratumoral and intertumoral heterogeneity of HER2 immunohistochemical expression in gastric cancer

    by He Zhang, Yi Wang, Yanfeng Wang, Daoyuan Wu, Enguang Lin, Qingxin Xia